Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 46%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics Inc exhibits a promising outlook due to its robust clinical data for icotrokinra, which demonstrates significant dose-dependent improvements in clinical response and remission rates over time, indicating strong potential for effective treatment in inflammatory diseases. The company’s strategic focus on building a diverse pipeline, including rusfertide and continued advancements in its proprietary technology platform, supports sustained growth and innovation within its therapeutic areas. Furthermore, the emphasis on business development and the anticipation of key catalysts in 2025 bolster confidence in the company's future performance and market position.

Bears say

Protagonist Therapeutics Inc faces a challenging outlook due to several significant financial and operational risks inherent in the biopharmaceutical industry. Key concerns include potential unexpected safety issues arising from ongoing clinical trials, the uncertainty of strategic partnerships that may curtail the development of icotrokinra, and escalating regulatory and pricing pressures that could impact market acceptance and profitability. Additionally, the company may encounter financial strain from future cash needs, raising the possibility of dilution for existing shareholders, further complicating its market position.

Protagonist Therapeutics (PTGX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 46% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 13 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.